

1 **Uterine fluid transcriptome as potential non-invasive biomarker for predicting endometrial receptivity**

2

3 Aihua He<sup>1,2†</sup>, Hong Wu<sup>3†</sup>, Yangyun Zou<sup>4</sup>, Cheng Wan<sup>4</sup>, Jing Zhao<sup>1,2</sup>, Qiong Zhang<sup>1,2</sup>, Nenghui Liu<sup>1,2</sup>, Donge  
4 Liu<sup>1,2</sup>, Yumei Li<sup>1,2</sup>, Jing Fu<sup>1,2</sup>, Hui Li<sup>1,2</sup>, Xi Huang<sup>1,2</sup>, Tianli Yang<sup>1,2</sup>, Chunxu Hu<sup>4</sup>, Zhaojuan Hou<sup>1,2</sup>, Yue  
5 Sun<sup>4</sup>, Xin Dong<sup>4</sup>, Jian Wu<sup>4</sup>, Sijia Lu<sup>4\*</sup>, Yanping Li<sup>1,2\*</sup>

6 <sup>1</sup> Department of Reproductive Medicine, Xiangya Hospital, Central South University, Changsha, Hunan,  
7 410000, China.

8 <sup>2</sup> Clinical Research Center for Women's Reproductive Health in Hunan Province, Changsha, Hunan, 410000,  
9 China.

10 <sup>3</sup> Department of ENT, Xiangya Hospital, Central South University, Changsha, Hunan, 410000, China

11 <sup>4</sup> Department of Clinical Research, Yikon Genomics Company, Ltd., Suzhou, Jiangsu, 215123, China.

12 \*For correspondence: liyanp@csu.edu.cn (YPL); lusijia@yikongenomics.com (SJL)

13 † These authors contributed equally to this work

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28 **Abstract**

29 **Background:** The synchrony between the embryo and the receptive endometrium is essential for successful  
30 implantation. Therefore, a reliable non-invasive ER prediction method is highly demanded. We aimed to  
31 establish a method that could be used to predict endometrium receptivity non-invasively and to evaluate its  
32 clinical application potential in patients undergoing IVF.

33 **Methods:** The non-invasive RNA-seq based endometrial receptivity test (nirsERT) was established by  
34 sequencing and analyzing the RNA of uterine fluid from 48 IVF patients with normal ER. Subsequently, 22  
35 IVF patients were recruited and analyzed the correlation between the predicted results of nirsERT and  
36 pregnancy outcomes.

37 **Results:** 87 marker genes and 3 hub genes were selected to establish the nirsERT. 10-fold cross-validation  
38 resulted in a mean accuracy of 93.0%. A small cohort retrospective observation showed that 77.8% (14/18) of  
39 IVF patients predicted with normal WOI had successful intrauterine pregnancies, while none of the 3 patients  
40 with displaced WOI had successful pregnancy.

41 **Conclusions:** nirsERT is potential for a non-invasive, accurate and same cycle testing for ER in reproductive  
42 clinic.

43 **Funding:** Funded by the National Natural Science Foundation of China (grant no. 8187061497) and the  
44 National Key Research and Developmental Program of China (grant no. 2018YFC1004800).

45 **Clinical trial number:** ChiCTR-DDD-17013375.

46 |

47 **Keywords:** Endometrial receptivity, window of implantation, transcriptomic profiling, machine learning,  
48 random forest algorithm, non-invasive biomarker.

49

## 50 **Introduction**

51 An ideal synchrony between the embryo and the receptive endometrium is necessary for successful  
52 implantation. The period of receptive endometrium, which referred to as window of implantation (WOI),  
53 normally occurs during the 19th to 24th day of a normal cycle. Previous studies demonstrated that the  
54 pregnancy rate would significantly reduce when implantation is not performed during the WOI [1, 2]. However,  
55 the optimal WOI lasts for less than 48 hours and varies wildly between individuals [3]. Abnormal  
56 endometrium receptivity (ER), including WOI shift and pathologic injury, has been observed in numerous  
57 patients with repeated implantation failure (RIF) [4-6]. Therefore, an approach of evaluating ER status is in  
58 urgent need, especially in the field of assisted reproductive technology (ART).

59 To fulfill this requirement, several methods had been proposed in the past decades, such as ultrasound  
60 examination [7-9], histologic analysis [10], and morphological markers [11-13]. But none had been proven to  
61 be an ideal predictor of endometrial receptivity. With the advance in molecular biological technologies, our  
62 understanding of molecular mechanism of embryo implantation has been significantly improved. In 2011, a  
63 238 gene endometrial receptivity array (ERA) using RNA expression microarray was published by Diaz-  
64 Gimeno et al [14]. The ERA method is capable of identifying different stages of endometrial cycle, which are  
65 known as pre-receptive (PR), receptive (RE), and post-receptive (PO). The accuracy and reproducibility was  
66 proven to be reliable in subsequent studies [15-17]. Several studies have demonstrated that pregnancy  
67 outcomes of patients with RIF and infertile couples with conventional IVF [17, 18] can be improved by  
68 personalized embryo transfer (pET) guided by the ERA test. In addition, relevant results indicate that  
69 transcriptomic and proteomic markers provide promising approaches for ER assessment. Although numerous  
70 differentially expressed genes (DEGs) that are involved in endometrial receptivity have been revealed by  
71 previous studies, the overlap between these results is rather poor. One explanation might be that the sample  
72 size, individual differences and microarray platforms differ between studies. The next-generation, high-  
73 throughput RNA sequencing (RNA-seq) provides another powerful tool for analyzing the whole transcriptome  
74 comprehensively. RNA-seq is better than microarray at dynamic range, background noises, and identifying  
75 different transcripts [19, 20]. Another limitation for current diagnostic tools of endometrial receptivity has  
76 been the necessity of invasive tissue sampling by endometrial biopsy. The endometrial RNA expression profile  
77 could be altered due to the small injuries caused by invasive sampling [21]. Besides, local injury to the  
78 endometrium was reported to have a negative impact on implantation [22], therefore, it is inappropriate to  
79 perform endometrial tissue sampling test and guide implantation in a same active cycle. It is necessary to  
80 develop a non-invasive diagnostic tool to accurately predict WOI.

81 Uterine fluids is the important medium of communication between embryo and endometrium. It is an  
82 admixture of endometrial secretions, plasma transudates, and oviductal fluid [23]. Uterine fluid contains  
83 extracellular vesicles, RNAs, DNAs, regulatory proteins, ions, lipids and other bioactive factors and plays an  
84 important role in embryo implantation [24]. Thus, high throughput sequencing of uterine fluid provides an

85 opportunity to find non-invasive biomarkers of endometrial receptivity for clinical use. Aspiration of uterine  
86 fluid prior to embryo transfer does not affect embryo implantation rate [25] also supports the feasibility of  
87 developing a non-invasive diagnostic tool based on uterine fluid. However, there are few transcriptional  
88 studies related to endometrial receptive markers from uterine fluid. A previous study [26] has identified a 53  
89 candidate genes predictive of endometrial receptivity by using microarray technology to analyze uterine fluid,  
90 but it has not been developed into clinical diagnostic test.

91 Here, the aim of our study was to investigate the feasibility of predicting ER with biomarkers from  
92 uterine fluid, and to establish a non-invasive RNA-seq based endometrium receptivity test (nirsERT) which  
93 has the potential to be used in reproductive clinic.

94

## 95 **Methods**

### 96 **Study Design**

97 The main objective of this study was to establish a prediction tool for endometrial receptivity using  
98 transcriptome sequencing data, and to evaluate the feasibility of non-invasive endometrial receptivity test using  
99 uterine fluid specimen. Firstly, from November 2017 to December 2018, participants were recruited to identify  
100 differentially expressed genes (DEGs) among pre-receptive, receptive and post-receptive endometrium by  
101 transcriptome sequencing and expression profile analysis and to build the nirsERT model applying machine  
102 learning algorithm of random forest (RF). To limit interference from confounding variables affecting ER, the  
103 inclusion criteria for IVF patients were as follows: 20-39 years of age; body mass index (BMI)=18–25 kg/m<sup>2</sup>;  
104 secondary infertility with a history of a intrauterine pregnancy/pregnancies and undergoing the first IVF cycle  
105 due to tubal factors; primary infertility undergoing the first IVF cycle due to male factors; a regular menstrual  
106 cycle length (25-35 days) with spontaneous ovulation; normal ovarian reserve (baseline FSH < 10 mIU/mL,  
107 antimullerian hormone > 1.5 ng/ml, antral follicle count > 5); able to be followed up to assess the pregnancy  
108 outcome, and successful intrauterine pregnancy after the first embryo transfer (ET). The intrauterine pregnancy  
109 was defined as the presence of a gestational sac with or without fetal heart activity in the uterine cavity as  
110 evaluated by ultrasound 4–5 weeks after ET. To establish the prediction tool, normal ER status was defined  
111 with successful intrauterine pregnancy.

112 Secondly, from January to April 2019, participants were recruited to demonstrate the accuracy of nirsERT  
113 in predicting WOI. The inclusion criteria for patients who collected uterine fluid on the day of blastocysts  
114 transfer were as follows: 20-39 years of age; BMI = 18–25 kg/m<sup>2</sup>; ultrasound showed endometrial thickness ≥  
115 8 cm and endogenous serum progesterone level ≤1.2ng/ml on the day of progesterone administration/LH peak;  
116 the transferred embryos were high-quality blastocysts (blastocysts ≥ 3 BB on Day 5 and Day 6, graded based  
117 on the Gardner system) [27].

118 The following exclusion criteria were applied: endometrial diseases (including intrauterine adhesions,  
119 endometrial polyps, endometritis, endometrial tuberculosis, endometrial hyperplasia, and a thin endometrium);  
120 hydrosalpinx without proximal tubal ligation; submucous myomas, intramural hysterosomyomas, or  
121 adenomyomas protruding towards the uterine cavity; endometriosis (stages III–IV); uterine malformations; and  
122 other medical or surgical co-morbidities were identified by consulting medical records, physical examination,  
123 blood test, B-ultrasound and X-ray examination.

124 In the validation group, all patients were performed nirsERT and were followed up to 4-5 weeks after ET  
125 to determine intrauterine pregnancy by ultrasound.

## 126 **Ethics statement**

127 The present study was conducted at the Center for Reproductive Medicine at Xiangya Hospital of  
128 Central South University with permission by the Ethics Committee of Reproductive Medicine. This study was  
129 registered with the Chinese Clinical Trial Registry (No. ChiCTR-DDD-17013375).

## 130 **Uterine fluid collection, processing and transcriptome sequencing**

131 All patients signed the written informed consent before sample collection. For patients included in the  
132 model construction, ultrasound was initiated from day 10 of the menstrual cycle preceding the IVF cycle to  
133 monitor ovulation. Blood LH levels were dynamically measured daily when the follicle diameter was > 14 mm.  
134 Patients continue to undergo daily ultrasound monitoring of ovulation until follicular discharge. Uterine fluid  
135 were respectively collected using embryo transfer catheter (Cook Medical; America) on days 5, 7, and 9  
136 (LH+5, LH+7, and LH+9, respectively) after the LH surge (denoted as LH+0). For patients in the model  
137 validation group, the uterine fluid was collected on the day of blastocyst transfer before embryo transfer.  
138 (Transfers of frozen-thawed blastocysts were performed on the 7 days after the LH surge of natural cycle / the  
139 5 days after progesterone supplementation of hormone replacement (HRT) cycles).

140 The sampling was performed as follows. The cervix was cleansed with saline before sampling. After  
141 the outer catheter of the embryo transfer catheter was inserted through the cervix to a depth of 4 cm from the  
142 external cervical os, the inner catheter was introduced into the uterine cavity to a point 1–2 cm from the uterine  
143 fundus to avoid contamination with cervical mucus. A 2.5 mL syringe was connected to the inner catheter and  
144 suction was applied. Inner catheter was withdrawn within the external catheter before external catheter was  
145 withdrawn from the uterus. Approximately 5-10uL of uterine fluid obtained were immediately placed into 20  
146 uL of RNA-later buffer (AM7020; Thermo Fisher Scientific, Waltham, MA, USA) for RNA stabilization,  
147 sealed, and cryopreserved at -20 °C. Sequencing analysis was carried out within 7 days after sampling.

148 Total RNA was extracted by using RNeasy Micro Kit (74004; Qiagen, city, state, country) according  
149 to the manufacturer's instruction. Quality control of RNA was performed with Qubit HS RNA Kit (Q32855;  
150 Invitrogen) and Agilent Bioanalyzer 2100 (Agilent Technologies, city, state, country). Reverse transcription

151 and library preparation were conducted using the MALBAC<sup>®</sup> Platinum single cell RNA amplification kit and  
152 Transposon library Prep kit (KT110700796, and XY045, Yikon Genomics, Suzhou, China). Qualified libraries  
153 were sequenced by using the Illumina HiSeq 2500 platform with single-end reads length of 140bp. An average  
154 number of 5 million reads was generated for each library.

### 155 **Detection of differentially expressed genes**

156 Differentially expressed genes (DEGs) among different endometrial receptivity conditions were  
157 identified by analysis of variance (ANOVA). The equation is stated as follows:

$$Y_{gijk} = \mu_g + T_{gi} + S_{gj} + \varepsilon_{gijk}$$

158 where  $\mu_g$  represents the mean expression level of gene  $g$ ;  $T_{gi}$  is gene-specific treatment effect referring to the  
159 status of being natural cycle or a hormone replacement therapy when uterine fluid was obtained,  $T_{gi} \sim (0, \sigma_{T_g}^2)$ ;  
160  $S_{gj}$  is gene-specific endometrial receptivity stage effect with three levels (pre-receptivity, receptivity, and post-  
161 receptivity),  $S_{gi} \sim (0, \sigma_{S_g}^2)$ ; and  $\varepsilon_{gijk}$  is gene-dependent residual error,  $\varepsilon_{gijk} \sim (0, \sigma_{\varepsilon_g}^2)$ . The F-test was applied to  
162 statistically assess the equality of variances between  $S_j$  and  $\varepsilon_{ijk}$  for each gene, showing whether the gene is  
163 differentially expressed among different endometrial receptivity stages. Because RNA-Seq analysis involves  
164 multiple statistical tests, the false discovery rate (FDR) was used to adjust the p-value (q-value) to provide  
165 statistical inference.

### 166 **Co-expression network construction and visualization**

167 Co-expression modules in the endometrial receptivity process were detected by weighted gene co-  
168 expression network analysis (WGCAN) [28]. Applying WGCNA, we then identified key modules significantly  
169 correlated with endometrial receptivity stages. Cytoscape software was then used to visualize the interaction  
170 networks with different co-expression key modules [29].

### 171 **Biomarker identification and performance validation**

172 To identify biomarkers for predictive model construction, post-hoc Tukey HSD (Honestly Significant  
173 Difference) test from ANOVA analysis was applied for pairwise comparisons of three receptive levels. Genes  
174 with significant differences of all pairwise test were detected for maximally distinguishing each receptive stage.  
175 Expression values of these biomarkers were then inputted as features for the machine learning method-random  
176 forest to train the pattern on three ER conditions (pre-receptivity, receptivity, and post-receptivity). The top  
177 important features (gene expression) were further selected by R package random Forest based on two measures  
178 (mean decrease accuracy and mean decrease gini). Out-of-bag (OOB) error, mean accuracy, sensitivity,  
179 specificity, positive predictive value, negative predictive value and F1 were determined from 10-fold cross-  
180 validation.

### 181 **Statistical analysis**

182 Continuous data subject to a normal distribution were expressed as the mean  $\pm$ SD. Continuous data  
183 subject to a skewed distribution were expressed as the median and inter-quartile range (IQR). Categorical data  
184 were expressed as counts and percentages, and were determined to be statistically significant using the chi-  
185 square test or Fisher's exact test. A two-side P-value equal or less than 0.05 was considered to be statistically  
186 significant. Statistical analysis was performed using IBM SPSS software (Version 23.0, IBM Corp.)

187

## 188 **Results**

### 189 **Participants**

190 To establish the nirsERT model, we collected uterine fluid of three different receptive stages (pre-  
191 receptive, receptive and post-receptive) from infertile patients with normal WOI timing for RNA-seq. 69  
192 participants were recruited and 21 patients who were not pregnant after the first embryo transfer were excluded,  
193 and 48 patients with successful intrauterine pregnancies were used to build nirsERT model (Figure 1). Baseline  
194 clinical characteristics are shown in supplementary Table S1.

### 195 **Uterine fluid RNA extraction and sequencing**

196 To perform the transcriptome sequencing, we collected 144 uterine fluid specimens from 48  
197 participants and extracted total RNA by using commercial kit. As expected, the yield of RNA was relative low,  
198 ranging from 0 to 1160ng, with an average of 148ng. Almost one third of RNA samples were below detection  
199 limit of Qubit RNA HS assay kit (0.25ng/ $\mu$ L). Normally, it's difficult to construct sequencing libraries starting  
200 with less than 1ng of total RNA. To address this, we utilized a commercial kit for reverse transcription and  
201 amplification with low amount of RNA.

202 We first validated the repeatability of transcriptome sequencing combined with above-mentioned kit  
203 (see supplementary methods). The Spearman correlation between different initial amounts of RNA was above  
204 0.95, showing a high stability and repeatability of this method with at least 0.2ng RNA (Supplementary Figure  
205 S1). Then, we processed the 144 RNA samples according to the same protocol. As result, 140 NGS libraries  
206 were successfully constructed and sequenced, generating an average of 5.5 million raw reads per library. 632  
207 million of high-quality reads, representing approximately 82.1% of raw data, were mapped to the human  
208 reference genome (Hg19). The number of mapped genes ranged from 9,591 to 17,913 in each library.

### 209 **DEGs detection and functional analysis**

210 To identify differentially expressed genes (DEGs) among pre-receptivity, receptivity, and post-  
211 receptivity stages, ANOVA (analysis of variance) was applied to process the log<sub>2</sub> transformed transcriptomic  
212 data. As result, 864 DEGs were detected within three different ER status. Notably, there are relatively more  
213 down-regulated DEGs between post-receptivity and receptivity status (Figure 2A). Unsupervised hierarchical  
214 clustering of the DEGs showed three distinct groups. GO analysis of these DEGs were conducted by DAVID

215 tool (20). The DEGs were significantly enriched in 71 biological process (BP) terms, 38 cellular component  
216 (CC) terms and 25 molecular function (MF) terms. The top 1 enriched term for each category are signal  
217 transduction (GO:0007165), cytoplasm (GO:0005737), and protein binding (GO:0005515), respectively (Table  
218 1 and Figure 2B).

219 To further investigate the functional module of DEGs in uterine fluid samples, we used the weighted  
220 gene co-expression network analysis (WGCNA) algorithm to analyze transcription regulatory networks. As  
221 result, 4 co-expression network modules with 3 being highly significant correlation with ER stages, which are  
222 METurquoise, MEyellow and MEblue modules. Four hub genes ECI2 (METurquoise), ATP6V1B2 (MEyellow),  
223 CXCL16 (MEblue) and SELP (MEgrey) were then identified based on the highest intramodular connectivity in  
224 four co-expression modules (Table 2). The METurquoise module includes the most of DEGs, representing 59.1%  
225 (511/864) of total DEGs. It also shows the most significant correlation with ER stages with the correlation  
226 value of -0.7. Functional enrichment analysis shows genes in METurquoise module involve in transcription  
227 regulation like epigenic modification related pathway; MEblue genes are enriched in GTPase mediated signal  
228 transduction, while MEyellow genes play roles in biomacromolecule transporting and cell-cell adherens  
229 junction. The result represents the whole involvement in endometrium-embryo crosstalk related biological  
230 processes of these DEGs detected in uterine fluid, which includes cell-cell communication, signal reception  
231 and transduction, and a series of cellular responses like transcription and translation of proteins responsible for  
232 embryo implantation.

### 233 **Establishing and validating the ER predictive tool**

234 With Tukey test from ANOVA analysis, we selected genes with different expression in each pairwise  
235 comparisons of receptive stages (pre-receptivity versus receptivity, receptivity versus post-receptivity, and pre-  
236 receptivity versus post-receptivity). We therefore applied the expression pattern of these DEGs as training  
237 features for ER status classification using the random forest method. The random forest-based feature  
238 importance analysis with a top contribution to the model prediction by the mean decrease accuracy and Gini  
239 index was performed (21), resulting 87 predictive markers (Table 3). To strengthen the power of the predictive  
240 tool, we include three hub genes as additional markers (Figure 3), resulting the nirsERT. Linear discriminant  
241 analysis (LDA) showed three ER conditions (pre-receptivity, receptivity, and post-receptivity) were distinctly  
242 classified by the expression pattern of these transcriptomic markers (Figure 4A). To assess the performances of  
243 the present predictor, a 10-fold cross-validation was applied. We got mean accuracy of 93.0%, mean  
244 specificity of 95.9%, mean sensitivity of 90.0%. Uterine fluid samples of different ER conditions could be well  
245 separated by setting as a probability threshold of 0.6 (Figure 4B).

### 246 **Retrospective observation of a small cohort of patients undergoing IVF**

247 To further evaluate the accuracy of the nirsERT, we analyzed the correlation between the predicted  
248 results of nirsERT and pregnancy outcomes. 22 uterine fluid samples from IVF patients were collected on the



249 day of blastocyst transfer before embryo transfer and tested. The intrauterine pregnancy was determined by  
250 ultrasound 28 days after embryos transferred. The success rate of sequencing was 95.4% (21/22), with 1  
251 libraries failed to pass the quality control procedure. As result, 18 patients (85.7%, 18/21) were predicted with  
252 normal WOI, whereas 3 (14.3%, 3/21) and 0 were predicted with delayed and advanced WOI, respectively.  
253 The intrauterine pregnancy rate (IPR) was 77.8% (14/18) among patients with normal WOI. There was no  
254 successful pregnancy in patients with displaced WOI, which was significantly different from those with normal  
255 WOI ( $P<0.05$ ). The overall IPR in all patients was 63.6% (14/22) (Table 4).

256

## 257 **Discussion**

258 In the past decades, researchers have investigated a variety of approaches to evaluate the condition of  
259 endometrial receptivity. However, limited progress had been made until the transcriptomic markers were  
260 established [26, 30]. Diagnostic tool result from endometrial tissue transcriptome is accurate and reproducible,  
261 but the application was also hindered by the necessity of invasive sampling. Thus, developing a non-invasive,  
262 precise and reliable method of ERT is one of the major challenges in reproductive medicine. In this study, a  
263 non-invasive ERT method based on RNA-seq was described for the first time, and it had the following benefits  
264 compared with previous studies: (1) RNA-seq could be used to identify more genes and in a more accurate  
265 manner than the conventional gene microarray; (2) Rather than two time points sampling, we collected  
266 samples of uterine fluid at three different time points, the pre-receptive, receptive, and post-receptive. Thus,  
267 the time span was shorten and a highly correlated sample cohort was established; (3) over 800 of DEGs in  
268 uterine fluid were analyzed, providing insight into function and role of multiple genes in the process of embryo  
269 implantation. It is difficult to perform transcriptome sequencing with uterine fluid samples, as nearly 1/3 of the  
270 samples yielded total RNA less than 0.25ng/ $\mu$ L. To address this, we utilized a commercial kit designed for  
271 single-cell RNA reverse transcription and amplification. The results showed a high stability and repeatability,  
272 the Spearman correlation between different amounts of total RNA ranging from 0.2ng to 20ng were above 0.98.  
273 By using this kit, we successfully prepared 140 RNA-seq libraries and constructed the training dataset.  
274 However, there were still 4 libraries failed to pass the quality control, we assume this might be caused by  
275 extremely low amount of RNA in these uterine fluid samples. To ensure the availability of nirsERT, it is  
276 important to investigate the distribution of the amount of total RNA in population. Besides, the improvement  
277 of uterine fluid aspiration could be helpful in further studies.

278 According to our previous study (preprinted) [31], there were 3571 DEGs identified from endometrial  
279 tissue among there ER status, a predictive tool (rsERT) consisted of 175 marker genes was established based  
280 on these DEGs. In current, a total of 864 DEGs were identified, including 468 common DEGs and 396 uterine  
281 fluid specific DEGs, compared with the study of rsERT. We found these common DEGs are significantly  
282 enriched in extracellular exosome (GO:0070062), cytoplasm (GO:0005737), cytosol (GO:0005829),

283 nucleoplasm (GO:0005654) and protein binding (GO:0005515), which support the scenario that RNAs in  
284 uterine fluid originated from endometrial tissue cell with exosome secreted the outside of the cell.  
285 Unexpectedly, 396 DEGs were specifically observed in uterine fluid samples. These genes significantly  
286 involve in integrin-mediated signaling pathway (GO:0007229) and immune responses like leukocyte migration  
287 (GO:0050900), inflammatory response (GO:0006954) and response to lipopolysaccharide (GO:0032496).  
288 Besides, approximately 38.2% (330 of 864) of total DEGs were previously reported [13, 14, 32-35], while 61.8%  
289 (534 of 864) were first identified to be differently expressed in all three status of receptive. Our findings  
290 highlight the importance of genes involved in protein binding, signal transduction, and leukocyte migration in  
291 the uterine fluid. For instance, DEGs enriched in extracellular exosome (GO:0070062), including SLC25A1  
292 (ENSG00000100075), PLSCR1 (ENSG00000188313), and NME3 (ENSG00000103024) were observed to be  
293 significantly related to the dynamic change of the sequential receptivity stages, which are assumed to mediate  
294 the communication between endometrium and embryo. Other cellular responses and signal transduction-  
295 related factors, e.g., RAC2 (ENSG00000128340) and ESR1 (ENSG00000091831), were also observed in our  
296 study (see Supplementary Table S2 and S3).

297 Four hub genes, ECI2, ATP6V1B2, CXCL16 and SELP were identified by using WGCNA analysis.  
298 ECI2 encodes a key mitochondrial enzyme involved in beta-oxidation of unsaturated fatty acids which may  
299 provide energy necessary for embryo implantation course. SELP implies the possible mechanism of P-selectin  
300 mediated cell adhesion in endometrium-embryo interaction. CXCL16 and its receptor CXCR6 were reported to  
301 play role in the decidualization during pregnancy [36]. ATP6V1B2 (ATPase H<sup>+</sup> Transporting V1 Subunit B2)  
302 is a transmembrane transporter, which may be responsible for transporting biomacromolecule like secretory  
303 protein to its target location like extracellular matrix.

304 nirsERT consisting of 87 markers and 3 hub genes were selected by using random forest algorithm among  
305 864 DEGs was established. We compared two predictive tools, nirsERT and rsERT established by using  
306 endometrial tissue samples in our previous study, only 22 markers were shared for both uterine fluid and tissue  
307 samples (Supplementary Table S4). According to the Human Protein Atlas, proteins generated by these gene  
308 locate in variety of subcellular locations [24], such as vesicle (BAG5, RAMP2), nucleus or nucleoplasm  
309 (ZNF652, TRAK1), cytosol (MAP2K6, RNF125) and cell junctions (PKP2). Besides, High correlation of  
310 expression pattern for these genes were observed between uterine fluid and endometrial tissue samples  
311 (Supplementary Figure S2). The results indicate the source of the common markers could be exfoliated  
312 endometrial cells or extracellular vesicles. The performance of nirsERT with rsERT was also compared study  
313 by using a same standard. 10-fold cross-validation resulted in comparable mean accuracy (93.0% vs 98.4%),  
314 mean specificity (95.9% vs 98.9%) and mean sensitivity (90% vs 97.8%).

315 We also investigated the selected markers in previous studies [14, 26], poor commonness was observed  
316 (Supplementary Figure S3). No common marker is selected in all three studies. There is no universal standard  
317 of selecting marker genes for endometrial receptivity, the mechanism of uterine transcriptomic changes during

318 the process of embryo implantation is still unrevealed. Further investigations are required for raising power  
319 and reproducibility of the endometrial receptivity prediction.

320 To verify the accuracy of nirsERT in predicting endometrial receptivity, the uterine fluid collected on the  
321 day of blastocyst transfer was performed nirsERT. The accuracy of nirsERT prediction was evaluated by  
322 analyzing the correlation between the predicted results and subsequent pregnancy outcomes. The results  
323 showed that 77.8% (14/18) of patients predicted with normal WOI had successful intrauterine pregnancies,  
324 while none of the 3 patients with displaced WOI had successful pregnancy. It is suggested that the failure of  
325 embryo implantation in patients with displaced WOI may be the result of embryo-endometrial asynchrony.  
326 Although there are still four unsuccessful intrauterine pregnancies in patients with normal WOI predicted by  
327 nirsERT, 77.8% of IRP is consistent with the view that endometrial factors are responsible for about two-thirds  
328 of embryo implantation [37, 38]. Therefore, the results also further clinically validated the accuracy of  
329 nirsERT in predicting WOI. Personalized embryo transfer (pET) guided by nirsERT can possibly contribute to  
330 restore the synchronicity of embryonic and endometrial development which promoted successful embryo  
331 implantation. In addition, clinical pregnancy rate of routine blastocyst transplantation in our center was 55-  
332 60%, while the overall intrauterine pregnancy rate of patients with aspiration of uterine fluid on the day of  
333 embryo transfer was 63.6%, suggesting that aspiration of uterine fluid did not affect the embryo implantation.  
334 nirsERT has the potential to detect and guide pET in a same active cycle contributing to the successful embryo  
335 implantation.

336 It follows that our method provides currently the most promising approach for ideal pET. However, there  
337 is an issue has to confront, which is that whether nirsERT can improve the pregnancy outcomes of IVF  
338 patients by guiding pET has not been demonstrated yet, and we think it would be better to design a randomized  
339 clinical trial in the future to verify the clinical application value of nirsERT. In addition, the mechanism of  
340 endometrial receptivity marker genes also needs further investigation so as to provide theoretical basis for  
341 clinical treatment strategy.

342

### 343 **Conclusions**

344 In conclusion, we established a non-invasive RNA-seq based endometrial receptivity test (nirsERT) by  
345 transcriptome sequencing analysis of uterine fluid combined with random forest algorithm. Endometrial  
346 receptive DEGs in uterine fluid may be derived from endometrial tissue cells and have an independent role in  
347 embryo implantation. nirsERT has the equivalent accuracy of endometrial receptive prediction to endometrium  
348 samples and is potential for a non-invasive, accurate and same cycle testing for endometrium receptivity in  
349 reproductive clinic.

350

351

## 352 **Acknowledgments**

353 We thank all patients and their family for the participation. We also thank Elsevier Author Services for  
354 preparation the Figure 3.

355

## 356 **Conflict of Interest**

357 All the authors have read the manuscript and approved this for submission as well as no competing interests.

358

## 359 **References**

- 360 1. Macklon NS, Stouffer RL, Giudice LC, Fauser BC: **The science behind 25 years of**  
361 **ovarian stimulation for in vitro fertilization.** *Endocr Rev* 2006, **27**:170-207.
- 362 2. Simon A, Laufer N: **Repeated implantation failure: clinical approach.** *Fertil Steril*  
363 2012, **97**:1039-1043.
- 364 3. Prapas Y, Prapas N, Jones EE, Duleba AJ, Olive DL, Chatziparasidou A, Vlassis G: **The**  
365 **window for embryo transfer in oocyte donation cycles depends on the duration of**  
366 **progesterone therapy.** *Hum Reprod* 1998, **13**:720-723.
- 367 4. Norwitz ER, Schust DJ, Fisher SJ: **Implantation and the survival of early pregnancy.**  
368 *N Engl J Med* 2001, **345**:1400-1408.
- 369 5. Galliano D, Bellver J, Díaz-García C, Simón C, Pellicer A: **ART and uterine pathology:**  
370 **how relevant is the maternal side for implantation?** *Hum Reprod Update* 2015, **21**:13-  
371 38.
- 372 6. Sebastian-Leon P, Garrido N, Remohí J, Pellicer A, Diaz-Gimeno P: **Asynchronous and**  
373 **pathological windows of implantation: two causes of recurrent implantation failure.**  
374 *Hum Reprod* 2018, **33**:626-635.
- 375 7. Zhao J, Zhang Q, Wang Y, Li Y: **Endometrial pattern, thickness and growth in**  
376 **predicting pregnancy outcome following 3319 IVF cycle.** *Reprod Biomed Online* 2014,  
377 **29**:291-298.
- 378 8. Zhao J, Zhang Q, Li Y: **The effect of endometrial thickness and pattern measured by**  
379 **ultrasonography on pregnancy outcomes during IVF-ET cycles.** *Reprod Biol*  
380 *Endocrinol* 2012, **10**:100.
- 381 9. Hou Z, Zhang Q, Zhao J, Xu A, He A, Huang X, Xie S, Fu J, Xiao L, Li Y: **Value of**  
382 **endometrial echo pattern transformation after hCG trigger in predicting IVF**  
383 **pregnancy outcome: a prospective cohort study.** *Reprod Biol Endocrinol* 2019, **17**:74.
- 384 10. Coutifaris C, Myers ER, Guzick DS, Diamond MP, Carson SA, Legro RS, McGovern  
385 PG, Schlaff WD, Carr BR, Steinkampf MP, et al: **Histological dating of timed**  
386 **endometrial biopsy tissue is not related to fertility status.** *Fertil Steril* 2004, **82**:1264-  
387 1272.
- 388 11. Zhu L, Che HS, Xiao L, Li YP: **Uterine peristalsis before embryo transfer affects the**  
389 **chance of clinical pregnancy in fresh and frozen-thawed embryo transfer cycles.**  
390 *Hum Reprod* 2014, **29**:1238-1243.
- 391 12. Qiong Z, Jie H, Yonggang W, Bin X, Jing Z, Yanping L: **Clinical validation of pinopode**  
392 **as a marker of endometrial receptivity: a randomized controlled trial.** *Fertil Steril*

- 393 2017, **108**:513-517 e512.
- 394 13. Hu S, Yao G, Wang Y, Xu H, Ji X, He Y, Zhu Q, Chen Z, Sun Y: **Transcriptomic**  
395 **changes during the pre-receptive to receptive transition in human endometrium**  
396 **detected by RNA-Seq.** *J Clin Endocrinol Metab* 2014, **99**:E2744-2753.
- 397 14. Diaz-Gimeno P, Horcajadas JA, Martinez-Conejero JA, Esteban FJ, Alama P, Pellicer A,  
398 Simon C: **A genomic diagnostic tool for human endometrial receptivity based on the**  
399 **transcriptomic signature.** *Fertil Steril* 2011, **95**:50-60, 60 e51-15.
- 400 15. Díaz-Gimeno P, Ruiz-Alonso M, Blesa D, Bosch N, Martínez-Conejero JA, Alamá P,  
401 Garrido N, Pellicer A, Simón C: **The accuracy and reproducibility of the endometrial**  
402 **receptivity array is superior to histology as a diagnostic method for endometrial**  
403 **receptivity.** *Fertil Steril* 2013, **99**:508-517.
- 404 16. Garrido-Gómez T, Ruiz-Alonso M, Blesa D, Diaz-Gimeno P, Vilella F, Simón C:  
405 **Profiling the gene signature of endometrial receptivity: clinical results.** *Fertil Steril*  
406 2013, **99**:1078-1085.
- 407 17. Ruiz-Alonso M, Blesa D, Díaz-Gimeno P, Gómez E, Fernández-Sánchez M, Carranza F,  
408 Carrera J, Vilella F, Pellicer A, Simón C: **The endometrial receptivity array for**  
409 **diagnosis and personalized embryo transfer as a treatment for patients with**  
410 **repeated implantation failure.** *Fertil Steril* 2013, **100**:818-824.
- 411 18. Simón C GC, Cabanillas S, Vladimirov I, Castellón G, Giles J, Boynukalin K, Findikli N,  
412 Bahçeci M, Ortega I, Vidal C, Funabiki M, Izquierdo A, López L, Portela S, Frantz N,  
413 Kulmann M, Taguchi S, Labarta E, Colucci F, Mackens S, Santamaría X, Muñoz E,  
414 Barrera S, García-Velasco JA, Fernández M, Ferrando M, Ruiz M, Mol BW, Valbuena D;  
415 ERA-RCT Study Consortium Group.: **A 5-year multicentre randomized controlled**  
416 **trial comparing personalized, frozen and fresh blastocyst transfer in IVF.** *Reprod*  
417 *Biomed Online* 2020, **41**:14.
- 418 19. Nagalakshmi U, Waern K, Snyder M: **RNA-Seq: a method for comprehensive**  
419 **transcriptome analysis.** *Curr Protoc Mol Biol* 2010, **Chapter 4**:Unit 4.11.11-13.
- 420 20. Sîrbu A, Kerr G, Crane M, Ruskin HJ: **RNA-Seq vs dual- and single-channel**  
421 **microarray data: sensitivity analysis for differential expression and clustering.** *PLoS*  
422 *One* 2012, **7**:e50986.
- 423 21. Kalma Y, Granot I, Gnainsky Y, Or Y, Czernobilsky B, Dekel N, Barash A: **Endometrial**  
424 **biopsy-induced gene modulation: first evidence for the expression of bladder-**  
425 **transmembranal uroplakin Ib in human endometrium.** *Fertil Steril* 2009, **91**:1042-  
426 1049, 1049.e1041-1049.
- 427 22. Karimzade MA, Oskouian H, Ahmadi S, Oskouian L: **Local injury to the endometrium**  
428 **on the day of oocyte retrieval has a negative impact on implantation in assisted**  
429 **reproductive cycles: a randomized controlled trial.** *Arch Gynecol Obstet* 2010,  
430 **281**:499-503.
- 431 23. Bhusane K, Bhutada S, Chaudhari U, Savardekar L, Katkam R, Sachdeva G: **Secrets of**  
432 **Endometrial Receptivity: Some Are Hidden in Uterine Secretome.** *Am J Reprod*  
433 *Immunol* 2016, **75**:226-236.
- 434 24. Thul PJ, Åkesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, Alm T, Asplund  
435 A, Björk L, Breckels LM, et al: **A subcellular map of the human proteome.** *Science*  
436 2017, **356**.
- 437 25. van der Gaast MH, Beier-Hellwig K, Fauser BC, Beier HM, Macklon NS: **Endometrial**  
438 **secretion aspiration prior to embryo transfer does not reduce implantation rates.**

- 439 *Reprod Biomed Online* 2003, **7**:105-109.
- 440 26. Chan C, Virtanen C, Winegarden NA, Colgan TJ, Brown TJ, Greenblatt EM: **Discovery**  
441 **of biomarkers of endometrial receptivity through a minimally invasive approach: a**  
442 **validation study with implications for assisted reproduction.** *Fertil Steril* 2013,  
443 **100**:810-817.
- 444 27. Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB: **Reprint of: Blastocyst**  
445 **score affects implantation and pregnancy outcome: towards a single blastocyst**  
446 **transfer.** *Fertil Steril* 2019, **112**:e81-e84.
- 447 28. Zhang B, Horvath S: **A general framework for weighted gene co-expression network**  
448 **analysis.** *Stat Appl Genet Mol Biol* 2005, **4**:Article17.
- 449 29. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski  
450 B, Ideker T: **Cytoscape: a software environment for integrated models of**  
451 **biomolecular interaction networks.** *Genome Res* 2003, **13**:2498-2504.
- 452 30. Suhorutshenko M, Kukushkina V, Velthut-Meikas A, Altmäe S, Peters M, Mägi R,  
453 Krjutškov K, Koel M, Codoñer FM, Martinez-Blanch JF, et al: **Endometrial receptivity**  
454 **revisited: endometrial transcriptome adjusted for tissue cellular heterogeneity.** *Hum*  
455 *Reprod* 2018, **33**:2074-2086.
- 456 31. Aihua H, Yangyun Z, Cheng W, Jing Z, Qiong Z, Zhongyuan Y, Fen T, Hong W, Xi H,  
457 Jing F, et al: **The Role of Transcriptomic Biomarkers of Endometrial Receptivity in**  
458 **Personalized Embryo Transfer for Patients with Repeated Implantation Failure.**  
459 *PREPRINT available at Research Square; DOI: 1021203/rs3rs-126797/v1* 2020.
- 460 32. Kao LC, Tulac S, Lobo S, Imani B, Yang JP, Germeyer A, Osteen K, Taylor RN, Lessey  
461 BA, Giudice LC: **Global gene profiling in human endometrium during the window of**  
462 **implantation.** *Endocrinology* 2002, **143**:2119-2138.
- 463 33. Borthwick JM, Charnock-Jones DS, Tom BD, Hull ML, Teirney R, Phillips SC, Smith  
464 SK: **Determination of the transcript profile of human endometrium.** *Mol Hum*  
465 *Reprod* 2003, **9**:19-33.
- 466 34. Altmäe S, Reimand J, Hovatta O, Zhang P, Kere J, Laisk T, Saare M, Peters M, Vilo J,  
467 Stavreus-Evers A, Salumets A: **Research resource: interactome of human embryo**  
468 **implantation: identification of gene expression pathways, regulation, and integrated**  
469 **regulatory networks.** *Mol Endocrinol* 2012, **26**:203-217.
- 470 35. Altmäe S, Koel M, Vösa U, Adler P, Suhorutshenko M, Laisk-Podar T, Kukushkina V,  
471 Saare M, Velthut-Meikas A, Krjutškov K, et al: **Meta-signature of human endometrial**  
472 **receptivity: a meta-analysis and validation study of transcriptomic biomarkers.** *Sci*  
473 *Rep* 2017, **7**:10077.
- 474 36. Mei J, Yan Y, Li SY, Zhou WJ, Zhang Q, Li MQ, Sun HX: **CXCL16/CXCR6**  
475 **interaction promotes endometrial decidualization via the PI3K/AKT pathway.**  
476 *Reproduction* 2019, **157**:273-282.
- 477 37. Messaoudi S, El Kasmi I, Bourdieu A, Crespo K, Bissonnette L, Le Saint C, Bissonnette  
478 F, Kadoch IJ: **15 years of transcriptomic analysis on endometrial receptivity: what**  
479 **have we learnt?** *Fertil Res Pract* 2019, **5**:9.
- 480 38. Craciunas L, Gallos I, Chu J, Bourne T, Quenby S, Brosens JJ, Coomarasamy A:  
481 **Conventional and modern markers of endometrial receptivity: a systematic review**  
482 **and meta-analysis.** *Hum Reprod Update* 2019, **25**:202-223.

483

484

485

**Table 1.** GO enrichment analysis of DEGs from uterine fluid samples.

Category	Term	Gene count	p-value	Fold Enrichment	FDR
<b>Biological Process</b>	GO:0007165~signal transduction	83	2.92E-05	1.59	0.05
	GO:0045944~positive regulation of transcription from RNA polymerase II promoter	60	1.40E-02	1.36	22.49
	GO:0000122~negative regulation of transcription from RNA polymerase II promoter	50	2.60E-03	1.54	4.61
	GO:0045893~positive regulation of transcription, DNA-templated	39	1.98E-03	1.68	3.53
	GO:0006357~regulation of transcription from RNA polymerase II promoter	36	8.56E-04	1.81	1.54
	GO:0006954~inflammatory response	26	3.67E-02	1.52	49.24
	GO:0043065~positive regulation of apoptotic process	24	9.19E-03	1.77	15.42
	GO:0050900~leukocyte migration	21	5.05E-07	3.82	0.00
	GO:0001525~angiogenesis	21	2.68E-03	2.09	4.75
	GO:0008360~regulation of cell shape	18	1.87E-04	2.85	0.34
<b>Cellular Component</b>	GO:0005737~cytoplasm	298	7.41E-08	1.30	0.00
	GO:0005634~nucleus	270	8.01E-03	1.13	10.94
	GO:0005829~cytosol	200	8.78E-07	1.37	0.00
	GO:0070062~extracellular exosome	183	1.55E-08	1.48	0.00
	GO:0005654~nucleoplasm	157	5.89E-04	1.28	0.85
	GO:0016020~membrane	146	2.40E-07	1.51	0.00
	GO:0005739~mitochondrion	81	2.41E-03	1.38	3.42
	GO:0005615~extracellular space	75	2.61E-02	1.27	31.66
	GO:0048471~perinuclear region of cytoplasm	38	3.75E-02	1.39	42.34
GO:0009986~cell surface	34	3.70E-02	1.43	41.92	
<b>Molecular Function</b>	GO:0005515~protein binding	492	2.66E-12	1.23	0.00
	GO:0044822~poly(A) RNA binding	72	3.03E-03	1.41	4.64
	GO:0008270~zinc ion binding	66	4.84E-02	1.24	54.05
	GO:0042803~protein homodimerization activity	46	2.32E-02	1.39	30.79
	GO:0043565~sequence-specific DNA binding	33	4.91E-02	1.40	54.63
	GO:0003682~chromatin binding	32	1.88E-03	1.80	2.90
	GO:0005102~receptor binding	27	1.07E-02	1.69	15.49
	GO:0003779~actin binding	26	9.10E-04	2.06	1.42
	GO:0008134~transcription factor binding	26	1.23E-03	2.02	1.90
	GO:0044212~transcription regulatory region DNA binding	17	3.33E-02	1.76	41.17

486

487

**Table 2.** WGCNA analysis of DEGs from uterine fluid.

Module	Number of genes	Hub gene	Module-receptivity relationships	DAVID cluster	*p-value	Enrichment score
ME turquoise	510	ECI2	-0.7	GO:0016575~histone deacetylation	0.0479	3.44
				GO:0004407~histone deacetylase activity	0.0371	
				GO:0016581~NuRD complex	0.0416	
ME blue	265	CXCL16	0.55	GO:0051056~regulation of small GTPase mediated signal transduction	0.0192	3.5
				GO:0043547~positive regulation of GTPase activity	0.0385	
				GO:0005096~GTPase activator activity	0.0557	
ME yellow	78	ATP6V1B2	0.69	GO:0042470~melanosome	0.0133	2.4
				GO:0045121~membrane raft	0.0935	
				GO:0005913~cell-cell adherens junction	0.0935	

488 \*: Benjamini adjusted p-value

489



**Table 3.** List of predictive markers selected by random forest algorithm

HGNC ID	Approved symbol	Approved name	Mean Decrease Accuracy
HGNC:9441	PRKX	protein kinase X-linked	5.21
HGNC:8910	PGR	progesterone receptor	5.05
HGNC:29545	SUDS3	SDS3 homolog, SIN3A corepressor complex component	4.95
HGNC:704	ARPC1B	actin related protein 2/3 complex subunit 1B	4.72
HGNC:12393	TTC3	tetratricopeptide repeat domain 3	4.69
HGNC:28149	PRR15L	proline rich 15 like	4.54
HGNC:7213	MPHOSPH10	M-phase phosphoprotein 10	4.53
HGNC:20313	PKHD1L1	PKHD1 like 1	4.51
HGNC:5157	HPRT1	hypoxanthine phosphoribosyltransferase 1	4.48
HGNC:17582	KAT6B	lysine acetyltransferase 6B	4.48
HGNC:18196	SOX7	SRY-box transcription factor 7	4.41
HGNC:23785	PIKFYVE	phosphoinositide kinase, FYVE-type zinc finger containing	4.4
HGNC:17814	SLF2	SMC5-SMC6 complex localization factor 2	4.36
HGNC:11107	SMARCD2	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 2	4.35
HGNC:4461	GPM6B	glycoprotein M6B	4.33
HGNC:2470	CSRP2	cysteine and glycine rich protein 2	4.31
HGNC:18854	CREB3L4	cAMP responsive element binding protein 3 like 4	4.31
HGNC:11615	TCEA3	transcription elongation factor A3	4.28
HGNC:17947	THEM4	thioesterase superfamily member 4	4.26
HGNC:2567	OFD1	OFD1 centriole and centriolar satellite protein	4.25
HGNC:4330	GLRX	glutaredoxin	4.24
HGNC:24663	RABGAP1L	RAB GTPase activating protein 1 like	4.2
HGNC:17811	AMOTL1	angiomin like 1	4.19
HGNC:4183	GBP2	guanylate binding protein 2	4.14
HGNC:26323	ANKRD35	ankyrin repeat domain 35	4.13
HGNC:14651	PPIH	peptidylprolyl isomerase H	4.11
HGNC:16462	STRBP	spermatid perinuclear RNA binding protein	4.08
HGNC:17717	STK39	serine/threonine kinase 39	4.05
HGNC:25585	OGFOD1	2-oxoglutarate and iron dependent oxygenase domain containing 1	4.04
HGNC:7784	NFIA	nuclear factor I A	4.02
HGNC:20340	PRICKLE2	prickle planar cell polarity protein 2	4
HGNC:9024	PKP2	plakophilin 2	3.99
HGNC:21923	STEAP4	STEAP4 metalloredutase	3.94
HGNC:4171	GATA2	GATA binding protein 2	3.93
HGNC:21150	RNF125	ring finger protein 125	3.89
HGNC:6846	MAP2K6	mitogen-activated protein kinase kinase 6	3.85
HGNC:411	ALDH3B2	aldehyde dehydrogenase 3 family member B2	3.85
HGNC:19300	STX19	syntaxin 19	3.83
HGNC:4881	HEY2	hes related family bHLH transcription factor with YRPW motif 2	3.83
HGNC:18296	PPP4R2	protein phosphatase 4 regulatory subunit 2	3.82

HGNC:5464	IGF1	insulin like growth factor 1	3.81
HGNC:28990	ZNF516	zinc finger protein 516	3.8
HGNC:25569	NKAPD1	NKAP domain containing 1	3.78
HGNC:10524	SALL1	spalt like transcription factor 1	3.76
HGNC:25764	RMI1	RecQ mediated genome instability 1	3.75
HGNC:17925	TFCP2L1	transcription factor CP2 like 1	3.74
HGNC:20814	ZNF436	zinc finger protein 436	3.74
HGNC:30447	PLD6	phospholipase D family member 6	3.74
HGNC:253	ADH5	alcohol dehydrogenase 5 (class III), chi polypeptide	3.72
HGNC:24944	DDIT4	DNA damage inducible transcript 4	3.71
HGNC:15513	SMYD3	SET and MYND domain containing 3	3.65
HGNC:29652	WDR77	WD repeat domain 77	3.61
HGNC:22201	TCAF1	TRPM8 channel associated factor 1	3.6
HGNC:8154	OPRK1	opioid receptor kappa 1	3.59
HGNC:8013	HMG5	high mobility group nucleosome binding domain 5	3.58
HGNC:18856	CREB3L1	cAMP responsive element binding protein 3 like 1	3.57
HGNC:28204	NTPCR	nucleoside-triphosphatase, cancer-related	3.57
HGNC:18122	SOX17	SRY-box transcription factor 17	3.54
HGNC:20150	RAB15	RAB15, member RAS oncogene family	3.52
HGNC:941	BAG5	BAG cochaperone 5	3.5
HGNC:7785	NFIB	nuclear factor I B	3.49
HGNC:9844	RAMP2	receptor activity modifying protein 2	3.48
HGNC:3821	FOXO3	forkhead box O3	3.46
HGNC:8995	PIP5K1B	phosphatidylinositol-4-phosphate 5-kinase type 1 beta	3.39
HGNC:33941	SLC35E2B	solute carrier family 35 member E2B	3.38
HGNC:4908	HIBCH	3-hydroxyisobutyryl-CoA hydrolase	3.36
HGNC:5209	HSD11B2	hydroxysteroid 11-beta dehydrogenase 2	3.35
HGNC:6813	MAGED1	MAGE family member D1	3.34
HGNC:18757	RHOBTB3	Rho related BTB domain containing 3	3.32
HGNC:4253	GGTA1	glycoprotein alpha-galactosyltransferase 1 (inactive)	3.32
HGNC:4254	GGTA2P	glycoprotein alpha-galactosyltransferase 2, pseudogene	3.29
HGNC:19990	ANAPC4	anaphase promoting complex subunit 4	3.24
HGNC:8062	NUP153	nucleoporin 153	3.23
HGNC:12805	XDH	xanthine dehydrogenase	3.23
HGNC:23696	TIPARP	TCDD inducible poly(ADP-ribose) polymerase	3.22
HGNC:19391	SOCS3	suppressor of cytokine signaling 3	3.21
HGNC:29147	ZNF652	zinc finger protein 652	3.2
HGNC:29947	TRAK1	trafficking kinesin protein 1	3.18
HGNC:13071	PATZ1	POZ/BTB and AT hook containing zinc finger 1	3.18
HGNC:1132	BTG3	BTG anti-proliferation factor 3	3.15
HGNC:30747	COPS2	COP9 signalosome subunit 2	3.13
HGNC:7541	MXRA7	matrix remodeling associated 7	3.13
HGNC:4403	GNG11	G protein subunit gamma 11	3.11
HGNC:31412	SWI5	SWI5 homologous recombination repair protein	3.11
HGNC:16841	LITAF	lipopolysaccharide induced TNF factor	3.1

HGNC:7852	NME4	NME/NM23 nucleoside diphosphate kinase 4	3.07
HGNC:7391	MSX1	msh homeobox 1	3.00

---

491

492

493


494

**Table 4.** nirsERT results and clinical outcomes of 22 patients undergoing IVF.

	<b>Normal WOI</b>	<b>Displaced WOI</b>		<b>P-value</b>	<b>Detection failed</b>	<b>Total</b>
		<b>delayed</b>	<b>advanced</b>			
Date of transfer	LH+7/P+5	LH+7/P+5	LH+7/P+5		LH+7/P+5	
Predicted result	Receptivity	Pre-receptivity	Post-receptivity		/	
No. of patients	18	3	0		1	22
No. of intrauterine pregnancy	14	0	0		0	14
Intrauterine pregnancy rate	77.8%(14/18)	0	0	0.026	0	63.6%(14/22)

495

496




497

498 **Figure 1.** Flow diagram of Establishing and application of the non-invasive RNA-seq based endometrial

499 receptivity test.

500




501


502

503

504

**Figure 2.** Differential expression analysis and functional enrichment among endometrial receptivity conditions.





510

511 **Figure 4.** Establishment and validation of the nirsERT. A. Clustering the training set with LDA by using  
512 selected predictive markers; B. Prediction results of training set samples, with probability threshold of 0.6.

513